Hims, Novo
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Deutsche Bank analyst George Hill raised the firm’s price target on Hims & Hers to $27 from $23 and keeps a Hold rating on the shares ...
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Hims & Hers Health, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beat ...
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
Hims & Hers Health, Inc. ( (HIMS) ) has released its Q3 earnings. Here is a breakdown of the information Hims & Hers Health, Inc.
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...
Stocktwits on MSN1d
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 PerformanceHims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback